ID

DB00785|APRD00890||

名称

Cryptenamine

描述

Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

cas号

1356-18-9

唯一标识码

QVO4N8484O

状态

solid

组

approved,

指示

For the treatment of hypertension.

药效学

Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

作用机制

Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Some evidence has suggested that cryptenamine acts in a similar fashion to atropine, which lowers the "rest and digest" activity of all muscles and glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive inhibitor of the muscarinic acetylcholine receptors (acetylcholine is the neurotransmitter used by the parasympathetic nervous system). Therefore muscarinic acetylcholine receptors will be listed as experimental targets for cryptenamine.

毒性

代谢

吸收

半衰期

分类

消除途径

种类

Alkaloids
D000470
Antihypertensive Agents
D000959
Cardiovascular Agents
D002317
Cevanes
D002595
Heterocyclic Compounds, Fused-Ring
D000072471
Veratrum Alkaloids
D014704

盐类

蛋白质结合

清除

同义词

国际品牌

UnitensenMEDA AB

配送量

产品

混合物

包装者

生产者

generic:否; url:; name;Medpointe pharmaceuticals medpointe healthcare inc

价格

受影响的生物体

Humans and other mammals

剂量

atc代码

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00346
Alfuzosin may increase the hypotensive activities of Cryptenamine.
DB01143
Cryptenamine may increase the hypotensive activities of Amifostine.
DB01119
Diazoxide may increase the hypotensive activities of Cryptenamine.
DB00422
Methylphenidate may decrease the antihypertensive activities of Cryptenamine.
DB06701
Dexmethylphenidate may decrease the antihypertensive activities of Cryptenamine.
DB08935
Cryptenamine may increase the hypotensive activities of Obinutuzumab.
DB00806
Pentoxifylline may increase the hypotensive activities of Cryptenamine.
DB00073
Cryptenamine may increase the hypotensive activities of Rituximab.
DB00035
Desmopressin may decrease the antihypertensive activities of Cryptenamine.
DB00091
Cyclosporine may decrease the antihypertensive activities of Cryptenamine.
DB00191
Phentermine may decrease the antihypertensive activities of Cryptenamine.
DB00211
Midodrine may decrease the antihypertensive activities of Cryptenamine.
DB00216
Eletriptan may decrease the antihypertensive activities of Cryptenamine.
DB00221
Isoetharine may decrease the antihypertensive activities of Cryptenamine.
DB00247
Methysergide may decrease the antihypertensive activities of Cryptenamine.
DB00248
Cabergoline may decrease the antihypertensive activities of Cryptenamine.
DB00289
Atomoxetine may decrease the antihypertensive activities of Cryptenamine.
DB00292
Etomidate may decrease the antihypertensive activities of Cryptenamine.
DB00315
Zolmitriptan may decrease the antihypertensive activities of Cryptenamine.
DB00320
Dihydroergotamine may decrease the antihypertensive activities of Cryptenamine.
DB00321
Amitriptyline may decrease the antihypertensive activities of Cryptenamine.
DB00344
Protriptyline may decrease the antihypertensive activities of Cryptenamine.
DB00353
Methylergometrine may decrease the antihypertensive activities of Cryptenamine.
DB00368
Norepinephrine may decrease the antihypertensive activities of Cryptenamine.
DB00370
Mirtazapine may decrease the antihypertensive activities of Cryptenamine.
DB00388
Phenylephrine may decrease the antihypertensive activities of Cryptenamine.
DB00397
Phenylpropanolamine may decrease the antihypertensive activities of Cryptenamine.
DB00420
Promazine may decrease the antihypertensive activities of Cryptenamine.
DB00450
Droperidol may decrease the antihypertensive activities of Cryptenamine.
DB00490
Buspirone may decrease the antihypertensive activities of Cryptenamine.
DB00540
Nortriptyline may decrease the antihypertensive activities of Cryptenamine.
DB00543
Amoxapine may decrease the antihypertensive activities of Cryptenamine.
DB00561
Doxapram may decrease the antihypertensive activities of Cryptenamine.
DB00572
Atropine may decrease the antihypertensive activities of Cryptenamine.
DB00589
Lisuride may decrease the antihypertensive activities of Cryptenamine.
DB00610
Metaraminol may decrease the antihypertensive activities of Cryptenamine.
DB00656
Trazodone may decrease the antihypertensive activities of Cryptenamine.
DB00668
Epinephrine may decrease the antihypertensive activities of Cryptenamine.
DB00669
Sumatriptan may decrease the antihypertensive activities of Cryptenamine.
DB00696
Ergotamine may decrease the antihypertensive activities of Cryptenamine.
DB00699
Nicergoline may decrease the antihypertensive activities of Cryptenamine.
DB00723
Methoxamine may decrease the antihypertensive activities of Cryptenamine.
DB00726
Trimipramine may decrease the antihypertensive activities of Cryptenamine.
DB00734
Risperidone may decrease the antihypertensive activities of Cryptenamine.
DB00777
Propiomazine may decrease the antihypertensive activities of Cryptenamine.
DB00802
Alfentanil may decrease the antihypertensive activities of Cryptenamine.
DB00813
Fentanyl may decrease the antihypertensive activities of Cryptenamine.
DB00816
Orciprenaline may decrease the antihypertensive activities of Cryptenamine.
DB00830
Phenmetrazine may decrease the antihypertensive activities of Cryptenamine.
DB00831
Trifluoperazine may decrease the antihypertensive activities of Cryptenamine.
DB00841
Dobutamine may decrease the antihypertensive activities of Cryptenamine.
DB00852
Pseudoephedrine may decrease the antihypertensive activities of Cryptenamine.
DB00865
Benzphetamine may decrease the antihypertensive activities of Cryptenamine.
DB00867
Ritodrine may decrease the antihypertensive activities of Cryptenamine.
DB00871
Terbutaline may decrease the antihypertensive activities of Cryptenamine.
DB00875
Flupentixol may decrease the antihypertensive activities of Cryptenamine.
DB00901
Bitolterol may decrease the antihypertensive activities of Cryptenamine.
DB00908
Quinidine may decrease the antihypertensive activities of Cryptenamine.
DB00918
Almotriptan may decrease the antihypertensive activities of Cryptenamine.
DB00935
Oxymetazoline may decrease the antihypertensive activities of Cryptenamine.
DB00937
Diethylpropion may decrease the antihypertensive activities of Cryptenamine.
DB00938
Salmeterol may decrease the antihypertensive activities of Cryptenamine.
DB00952
Naratriptan may decrease the antihypertensive activities of Cryptenamine.
DB00953
Rizatriptan may decrease the antihypertensive activities of Cryptenamine.
DB00983
Formoterol may decrease the antihypertensive activities of Cryptenamine.
DB00988
Dopamine may decrease the antihypertensive activities of Cryptenamine.
DB00998
Frovatriptan may decrease the antihypertensive activities of Cryptenamine.
DB01001
Salbutamol may decrease the antihypertensive activities of Cryptenamine.
DB01028
Methoxyflurane may decrease the antihypertensive activities of Cryptenamine.
DB01049
Ergoloid mesylate may decrease the antihypertensive activities of Cryptenamine.
DB01064
Isoprenaline may decrease the antihypertensive activities of Cryptenamine.
DB01102
Arbutamine may decrease the antihypertensive activities of Cryptenamine.
DB01126
Dutasteride may decrease the antihypertensive activities of Cryptenamine.
DB01142
Doxepin may decrease the antihypertensive activities of Cryptenamine.
DB01149
Nefazodone may decrease the antihypertensive activities of Cryptenamine.
DB01151
Desipramine may decrease the antihypertensive activities of Cryptenamine.
DB01182
Propafenone may decrease the antihypertensive activities of Cryptenamine.
DB01186
Pergolide may decrease the antihypertensive activities of Cryptenamine.
DB01216
Finasteride may decrease the antihypertensive activities of Cryptenamine.
DB01253
Ergometrine may decrease the antihypertensive activities of Cryptenamine.
DB01255
Lisdexamfetamine may decrease the antihypertensive activities of Cryptenamine.
DB01267
Paliperidone may decrease the antihypertensive activities of Cryptenamine.
DB01274
Arformoterol may decrease the antihypertensive activities of Cryptenamine.
DB01288
Fenoterol may decrease the antihypertensive activities of Cryptenamine.
DB01291
Pirbuterol may decrease the antihypertensive activities of Cryptenamine.
DB01363
Ephedra sinica root may decrease the antihypertensive activities of Cryptenamine.
DB01364
Ephedrine may decrease the antihypertensive activities of Cryptenamine.
DB01365
Mephentermine may decrease the antihypertensive activities of Cryptenamine.
DB01366
Procaterol may decrease the antihypertensive activities of Cryptenamine.
DB01392
Yohimbine may decrease the antihypertensive activities of Cryptenamine.
DB01403
Methotrimeprazine may decrease the antihypertensive activities of Cryptenamine.
DB01407
Clenbuterol may decrease the antihypertensive activities of Cryptenamine.
DB01408
Bambuterol may decrease the antihypertensive activities of Cryptenamine.
DB01442
MMDA may decrease the antihypertensive activities of Cryptenamine.
DB01454
Midomafetamine may decrease the antihypertensive activities of Cryptenamine.
DB01467
2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Cryptenamine.
DB01472
4-Methoxyamphetamine may decrease the antihypertensive activities of Cryptenamine.
DB01484
4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Cryptenamine.
DB01509
Tenamfetamine may decrease the antihypertensive activities of Cryptenamine.
DB01556
Chlorphentermine may decrease the antihypertensive activities of Cryptenamine.
DB01576
Dextroamphetamine may decrease the antihypertensive activities of Cryptenamine.
DB01577
Metamfetamine may decrease the antihypertensive activities of Cryptenamine.
DB01579
Phendimetrazine may decrease the antihypertensive activities of Cryptenamine.
DB01591
Solifenacin may decrease the antihypertensive activities of Cryptenamine.
DB01608
Periciazine may decrease the antihypertensive activities of Cryptenamine.
DB01614
Acepromazine may decrease the antihypertensive activities of Cryptenamine.
DB01622
Thioproperazine may decrease the antihypertensive activities of Cryptenamine.
DB01624
Zuclopenthixol may decrease the antihypertensive activities of Cryptenamine.
DB02032
Epicaptopril may decrease the antihypertensive activities of Cryptenamine.
DB04581
1-benzylimidazole may decrease the antihypertensive activities of Cryptenamine.
DB04829
Lysergic acid diethylamide may decrease the antihypertensive activities of Cryptenamine.
DB04836
Amineptine may decrease the antihypertensive activities of Cryptenamine.
DB04855
Dronedarone may decrease the antihypertensive activities of Cryptenamine.
DB04908
Flibanserin may decrease the antihypertensive activities of Cryptenamine.
DB04946
Iloperidone may decrease the antihypertensive activities of Cryptenamine.
DB05039
Indacaterol may decrease the antihypertensive activities of Cryptenamine.
DB05395
Amibegron may decrease the antihypertensive activities of Cryptenamine.
DB05562
Naluzotan may decrease the antihypertensive activities of Cryptenamine.
DB06016
Cariprazine may decrease the antihypertensive activities of Cryptenamine.
DB06148
Mianserin may decrease the antihypertensive activities of Cryptenamine.
DB06152
Nylidrin may decrease the antihypertensive activities of Cryptenamine.
DB06153
Pizotifen may decrease the antihypertensive activities of Cryptenamine.
DB06190
Solabegron may decrease the antihypertensive activities of Cryptenamine.
DB06216
Asenapine may decrease the antihypertensive activities of Cryptenamine.
DB06262
Droxidopa may decrease the antihypertensive activities of Cryptenamine.
DB06678
Esmirtazapine may decrease the antihypertensive activities of Cryptenamine.
DB06684
Vilazodone may decrease the antihypertensive activities of Cryptenamine.
DB06690
Nitrous oxide may decrease the antihypertensive activities of Cryptenamine.
DB06694
Xylometazoline may decrease the antihypertensive activities of Cryptenamine.
DB06706
Isometheptene may decrease the antihypertensive activities of Cryptenamine.
DB06707
Levonordefrin may decrease the antihypertensive activities of Cryptenamine.
DB06711
Naphazoline may decrease the antihypertensive activities of Cryptenamine.
DB06763
Saralasin may decrease the antihypertensive activities of Cryptenamine.
DB06764
Tetryzoline may decrease the antihypertensive activities of Cryptenamine.
DB08810
Cinitapride may decrease the antihypertensive activities of Cryptenamine.
DB08815
Lurasidone may decrease the antihypertensive activities of Cryptenamine.
DB08841
Tyramine may decrease the antihypertensive activities of Cryptenamine.
DB08893
Mirabegron may decrease the antihypertensive activities of Cryptenamine.
DB08925
Adrafinil may decrease the antihypertensive activities of Cryptenamine.
DB08954
Ifenprodil may decrease the antihypertensive activities of Cryptenamine.
DB08957
Hexoprenaline may decrease the antihypertensive activities of Cryptenamine.
DB08985
Etilefrine may decrease the antihypertensive activities of Cryptenamine.
DB08996
Dimetacrine may decrease the antihypertensive activities of Cryptenamine.
DB09016
Butriptyline may decrease the antihypertensive activities of Cryptenamine.
DB09061
Cannabidiol may decrease the antihypertensive activities of Cryptenamine.
DB09068
Vortioxetine may decrease the antihypertensive activities of Cryptenamine.
DB09080
Olodaterol may decrease the antihypertensive activities of Cryptenamine.
DB09082
Vilanterol may decrease the antihypertensive activities of Cryptenamine.
DB09128
Brexpiprazole may decrease the antihypertensive activities of Cryptenamine.
DB09167
Dosulepin may decrease the antihypertensive activities of Cryptenamine.
DB09202
Cirazoline may decrease the antihypertensive activities of Cryptenamine.
DB09203
Synephrine may decrease the antihypertensive activities of Cryptenamine.
DB09205
Moxisylyte may decrease the antihypertensive activities of Cryptenamine.
DB09289
Tianeptine may decrease the antihypertensive activities of Cryptenamine.
DB09307
Oxaprotiline may decrease the antihypertensive activities of Cryptenamine.
DB09480
Iofetamine I-123 may decrease the antihypertensive activities of Cryptenamine.
DB11124
Racepinephrine may decrease the antihypertensive activities of Cryptenamine.
DB11273
Dihydroergocornine may decrease the antihypertensive activities of Cryptenamine.
DB11278
DL-Methylephedrine may decrease the antihypertensive activities of Cryptenamine.
DB11373
Amitraz may decrease the antihypertensive activities of Cryptenamine.
DB11428
Medetomidine may decrease the antihypertensive activities of Cryptenamine.
DB11477
Xylazine may decrease the antihypertensive activities of Cryptenamine.
DB11481
Atipamezole may decrease the antihypertensive activities of Cryptenamine.
DB11541
Ractopamine may decrease the antihypertensive activities of Cryptenamine.
DB11543
Romifidine may decrease the antihypertensive activities of Cryptenamine.
DB11556
Detomidine may decrease the antihypertensive activities of Cryptenamine.
DB11587
Etafedrine may decrease the antihypertensive activities of Cryptenamine.
DB11755
Tetrahydrocannabivarin may decrease the antihypertensive activities of Cryptenamine.
DB11785
Anisodamine may decrease the antihypertensive activities of Cryptenamine.
DB11871
PF-00610355 may decrease the antihypertensive activities of Cryptenamine.
DB12080
Ritobegron may decrease the antihypertensive activities of Cryptenamine.
DB12100
Abediterol may decrease the antihypertensive activities of Cryptenamine.
DB12248
Tulobuterol may decrease the antihypertensive activities of Cryptenamine.
DB12278
Propiverine may decrease the antihypertensive activities of Cryptenamine.
DB12313
Dopexamine may decrease the antihypertensive activities of Cryptenamine.
DB12361
Piclozotan may decrease the antihypertensive activities of Cryptenamine.
DB12371
Siponimod may decrease the antihypertensive activities of Cryptenamine.
DB12551
Idazoxan may decrease the antihypertensive activities of Cryptenamine.
DB12779
Higenamine may decrease the antihypertensive activities of Cryptenamine.
DB12846
Reproterol may decrease the antihypertensive activities of Cryptenamine.
DB12927
Theodrenaline may decrease the antihypertensive activities of Cryptenamine.
DB12930
Opipramol may decrease the antihypertensive activities of Cryptenamine.
DB13064
Tramazoline may decrease the antihypertensive activities of Cryptenamine.
DB13108
Mephedrone may decrease the antihypertensive activities of Cryptenamine.
DB13114
Amitriptylinoxide may decrease the antihypertensive activities of Cryptenamine.
DB13139
Levosalbutamol may decrease the antihypertensive activities of Cryptenamine.
DB13225
Dibenzepin may decrease the antihypertensive activities of Cryptenamine.
DB13246
Quinupramine may decrease the antihypertensive activities of Cryptenamine.
DB13251
Octopamine may decrease the antihypertensive activities of Cryptenamine.
DB13323
Trichloroethylene may decrease the antihypertensive activities of Cryptenamine.
DB13341
Fenozolone may decrease the antihypertensive activities of Cryptenamine.
DB13345
Dihydroergocristine may decrease the antihypertensive activities of Cryptenamine.
DB13378
Norfenefrine may decrease the antihypertensive activities of Cryptenamine.
DB13384
Melitracen may decrease the antihypertensive activities of Cryptenamine.
DB13385
Dihydroergocryptine may decrease the antihypertensive activities of Cryptenamine.
DB13398
Oxyfedrine may decrease the antihypertensive activities of Cryptenamine.
DB13399
Terguride may decrease the antihypertensive activities of Cryptenamine.
DB13411
Lofepramine may decrease the antihypertensive activities of Cryptenamine.
DB13453
Xenon may decrease the antihypertensive activities of Cryptenamine.
DB13496
Iprindole may decrease the antihypertensive activities of Cryptenamine.
DB13510
Buflomedil may decrease the antihypertensive activities of Cryptenamine.
DB13520
Metergoline may decrease the antihypertensive activities of Cryptenamine.
DB13559
Rimiterol may decrease the antihypertensive activities of Cryptenamine.
DB13598
Diethyl ether may decrease the antihypertensive activities of Cryptenamine.
DB13624
Methoxyphenamine may decrease the antihypertensive activities of Cryptenamine.
DB13692
Tretoquinol may decrease the antihypertensive activities of Cryptenamine.
DB13703
Gepefrine may decrease the antihypertensive activities of Cryptenamine.
DB13777
Prenalterol may decrease the antihypertensive activities of Cryptenamine.
DB13781
Xamoterol may decrease the antihypertensive activities of Cryptenamine.
DB13782
Imipramine oxide may decrease the antihypertensive activities of Cryptenamine.
DB13852
Mefenorex may decrease the antihypertensive activities of Cryptenamine.
DB13917
Deoxyepinephrine may decrease the antihypertensive activities of Cryptenamine.
DB13940
2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Cryptenamine.
DB14010
5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Cryptenamine.
DB14231
Quinoline Yellow WS may decrease the antihypertensive activities of Cryptenamine.
DB14754
Solriamfetol may decrease the antihypertensive activities of Cryptenamine.
DB00363
Clozapine may decrease the antihypertensive activities of Cryptenamine.
DB00458
Imipramine may decrease the antihypertensive activities of Cryptenamine.
DB00477
Chlorpromazine may decrease the antihypertensive activities of Cryptenamine.
DB00633
Dexmedetomidine may decrease the antihypertensive activities of Cryptenamine.
DB00679
Thioridazine may decrease the antihypertensive activities of Cryptenamine.
DB00692
Phentolamine may decrease the antihypertensive activities of Cryptenamine.
DB00708
Sufentanil may decrease the antihypertensive activities of Cryptenamine.
DB00753
Isoflurane may decrease the antihypertensive activities of Cryptenamine.
DB00797
Tolazoline may decrease the antihypertensive activities of Cryptenamine.
DB00818
Propofol may decrease the antihypertensive activities of Cryptenamine.
DB00899
Remifentanil may decrease the antihypertensive activities of Cryptenamine.
DB00925
Phenoxybenzamine may decrease the antihypertensive activities of Cryptenamine.
DB01018
Guanfacine may decrease the antihypertensive activities of Cryptenamine.
DB01159
Halothane may decrease the antihypertensive activities of Cryptenamine.
DB01189
Desflurane may decrease the antihypertensive activities of Cryptenamine.
DB01200
Bromocriptine may decrease the antihypertensive activities of Cryptenamine.
DB01236
Sevoflurane may decrease the antihypertensive activities of Cryptenamine.
DB01242
Clomipramine may decrease the antihypertensive activities of Cryptenamine.
DB04948
Lofexidine may decrease the antihypertensive activities of Cryptenamine.
DB05271
Rotigotine may decrease the antihypertensive activities of Cryptenamine.
DB08941
Isoxsuprine may decrease the antihypertensive activities of Cryptenamine.
DB08950
Indoramin may decrease the antihypertensive activities of Cryptenamine.
DB09242
Moxonidine may decrease the antihypertensive activities of Cryptenamine.
DB00945
Acetylsalicylic acid may decrease the antihypertensive activities of Cryptenamine.
DB15685
Selpercatinib may decrease the antihypertensive activities of Cryptenamine.
DB15965
Naxitamab may decrease the antihypertensive activities of Cryptenamine.
DB09282
Molsidomine may increase the hypotensive activities of Cryptenamine.
DB00212
Remikiren may increase the hypotensive activities of Cryptenamine.
DB00217
Bethanidine may increase the hypotensive activities of Cryptenamine.
DB00226
Guanadrel may increase the hypotensive activities of Cryptenamine.
DB00287
Travoprost may increase the hypotensive activities of Cryptenamine.
DB00521
Carteolol may increase the hypotensive activities of Cryptenamine.
DB00559
Bosentan may increase the hypotensive activities of Cryptenamine.
DB00616
Candoxatril may increase the hypotensive activities of Cryptenamine.
DB00629
Guanabenz may increase the hypotensive activities of Cryptenamine.
DB00765
Metyrosine may increase the hypotensive activities of Cryptenamine.
DB00866
Cryptenamine may increase the hypotensive activities of Alprenolol.
DB00869
Cryptenamine may increase the hypotensive activities of Dorzolamide.
DB00886
Cryptenamine may increase the hypotensive activities of Omapatrilat.
DB00905
Cryptenamine may increase the hypotensive activities of Bimatoprost.
DB01089
Cryptenamine may increase the hypotensive activities of Deserpidine.
DB01090
Cryptenamine may increase the hypotensive activities of Pentolinium.
DB01116
Cryptenamine may increase the hypotensive activities of Trimethaphan.
DB01170
Cryptenamine may increase the hypotensive activities of Guanethidine.
DB01180
Cryptenamine may increase the hypotensive activities of Rescinnamine.
DB01214
Cryptenamine may increase the hypotensive activities of Metipranolol.
DB01295
Cryptenamine may increase the hypotensive activities of Bevantolol.
DB01297
Cryptenamine may increase the hypotensive activities of Practolol.
DB01347
Cryptenamine may increase the hypotensive activities of Saprisartan.
DB01348
Cryptenamine may increase the hypotensive activities of Spirapril.
DB01388
Cryptenamine may increase the hypotensive activities of Mibefradil.
DB03322
Cryptenamine may increase the hypotensive activities of Dexpropranolol.
DB04831
Cryptenamine may increase the hypotensive activities of Tienilic acid.
DB04840
Cryptenamine may increase the hypotensive activities of Debrisoquine.
DB04846
Cryptenamine may increase the hypotensive activities of Celiprolol.
DB06268
Cryptenamine may increase the hypotensive activities of Sitaxentan.
DB06403
Cryptenamine may increase the hypotensive activities of Ambrisentan.
DB06445
Cryptenamine may increase the hypotensive activities of Diethylnorspermine.
DB06762
Cryptenamine may increase the hypotensive activities of Pinacidil.
DB06826
Cryptenamine may increase the hypotensive activities of Unoprostone.
DB07767
Cryptenamine may increase the hypotensive activities of Ferulic acid.
DB08808
Cryptenamine may increase the hypotensive activities of Bupranolol.
DB08836
Cryptenamine may increase the hypotensive activities of Temocapril.
DB08932
Cryptenamine may increase the hypotensive activities of Macitentan.
DB08952
Cryptenamine may increase the hypotensive activities of Indenolol.
DB08960
Cryptenamine may increase the hypotensive activities of Hexamethonium.
DB09206
Cryptenamine may increase the hypotensive activities of Trimazosin.
DB09220
Cryptenamine may increase the hypotensive activities of Nicorandil.
DB09238
Cryptenamine may increase the hypotensive activities of Manidipine.
DB09239
Cryptenamine may increase the hypotensive activities of Niguldipine.
DB09363
Cryptenamine may increase the hypotensive activities of Rauwolfia serpentina root.
DB11362
Cryptenamine may increase the hypotensive activities of Selexipag.
DB11720
Cryptenamine may increase the hypotensive activities of Angiotensin 1-7.
DB11738
Cryptenamine may increase the hypotensive activities of Rilmenidine.
DB11770
Cryptenamine may increase the hypotensive activities of Talinolol.
DB12054
Cryptenamine may increase the hypotensive activities of BQ-123.
DB12092
Cryptenamine may increase the hypotensive activities of Naftopidil.
DB12093
Cryptenamine may increase the hypotensive activities of Tetrahydropalmatine.
DB12212
Cryptenamine may increase the hypotensive activities of Landiolol.
DB12465
Cryptenamine may increase the hypotensive activities of Ketanserin.
DB12661
Cryptenamine may increase the hypotensive activities of Urapidil.
DB12766
Cryptenamine may increase the hypotensive activities of Cicletanine.
DB12945
Cryptenamine may increase the hypotensive activities of Dihydralazine.
DB13166
Cryptenamine may increase the hypotensive activities of Zofenopril.
DB13211
Cryptenamine may increase the hypotensive activities of Guanoxan.
DB13312
Cryptenamine may increase the hypotensive activities of Delapril.
DB13374
Cryptenamine may increase the hypotensive activities of Vincamine.
DB13400
Cryptenamine may increase the hypotensive activities of Linsidomine.
DB13410
Cryptenamine may increase the hypotensive activities of Guanoxabenz.
DB13429
Cryptenamine may increase the hypotensive activities of Tolonidine.
DB13435
Cryptenamine may increase the hypotensive activities of Endralazine.
DB13443
Cryptenamine may increase the hypotensive activities of Esatenolol.
DB13452
Cryptenamine may increase the hypotensive activities of Cadralazine.
DB13508
Cryptenamine may increase the hypotensive activities of Cloranolol.
DB13575
Cryptenamine may increase the hypotensive activities of Bietaserpine.
DB13604
Cryptenamine may increase the hypotensive activities of Guanazodine.
DB13631
Cryptenamine may increase the hypotensive activities of Methoserpidine.
DB13757
Cryptenamine may increase the hypotensive activities of Epanolol.
DB13779
Cryptenamine may increase the hypotensive activities of Guanoclor.
DB13801
Cryptenamine may increase the hypotensive activities of Muzolimine.
DB13803
Cryptenamine may increase the hypotensive activities of Xipamide.
DB13919
Cryptenamine may increase the hypotensive activities of Candesartan.
DB14068
Cryptenamine may increase the hypotensive activities of Dexniguldipine.
DB14094
Cryptenamine may increase the hypotensive activities of Tocopherylquinone.
DB14125
Cryptenamine may increase the hypotensive activities of Benazeprilat.
DB14207
Cryptenamine may increase the hypotensive activities of Fosinoprilat.
DB14208
Cryptenamine may increase the hypotensive activities of Ramiprilat.
DB14213
Cryptenamine may increase the hypotensive activities of Perindoprilat.
DB14217
Cryptenamine may increase the hypotensive activities of Quinaprilat.
DB00177
Valsartan may increase the hypotensive activities of Cryptenamine.
DB00178
Ramipril may increase the hypotensive activities of Cryptenamine.
DB00187
Esmolol may increase the hypotensive activities of Cryptenamine.
DB00195
Betaxolol may increase the hypotensive activities of Cryptenamine.
DB00206
Reserpine may increase the hypotensive activities of Cryptenamine.
DB00214
Torasemide may increase the hypotensive activities of Cryptenamine.
DB00264
Metoprolol may increase the hypotensive activities of Cryptenamine.
DB00270
Isradipine may increase the hypotensive activities of Cryptenamine.
DB00275
Olmesartan may increase the hypotensive activities of Cryptenamine.
DB00310
Chlorthalidone may increase the hypotensive activities of Cryptenamine.
DB00325
Nitroprusside may increase the hypotensive activities of Cryptenamine.
DB00335
Atenolol may increase the hypotensive activities of Cryptenamine.
DB00343
Diltiazem may increase the hypotensive activities of Cryptenamine.
DB00350
Minoxidil may increase the hypotensive activities of Cryptenamine.
DB00373
Timolol may increase the hypotensive activities of Cryptenamine.
DB00381
Amlodipine may increase the hypotensive activities of Cryptenamine.
DB00393
Nimodipine may increase the hypotensive activities of Cryptenamine.
DB00401
Nisoldipine may increase the hypotensive activities of Cryptenamine.
DB00492
Fosinopril may increase the hypotensive activities of Cryptenamine.
DB00519
Trandolapril may increase the hypotensive activities of Cryptenamine.
DB00524
Metolazone may increase the hypotensive activities of Cryptenamine.
DB00528
Lercanidipine may increase the hypotensive activities of Cryptenamine.
DB00542
Benazepril may increase the hypotensive activities of Cryptenamine.
DB00571
Propranolol may increase the hypotensive activities of Cryptenamine.
DB00584
Enalapril may increase the hypotensive activities of Cryptenamine.
DB00590
Doxazosin may increase the hypotensive activities of Cryptenamine.
DB00598
Labetalol may increase the hypotensive activities of Cryptenamine.
DB00612
Bisoprolol may increase the hypotensive activities of Cryptenamine.
DB00622
Nicardipine may increase the hypotensive activities of Cryptenamine.
DB00657
Mecamylamine may increase the hypotensive activities of Cryptenamine.
DB00678
Losartan may increase the hypotensive activities of Cryptenamine.
DB00691
Moexipril may increase the hypotensive activities of Cryptenamine.
DB00695
Furosemide may increase the hypotensive activities of Cryptenamine.
DB00700
Eplerenone may increase the hypotensive activities of Cryptenamine.
DB00722
Lisinopril may increase the hypotensive activities of Cryptenamine.
DB00727
Nitroglycerin may increase the hypotensive activities of Cryptenamine.
DB00790
Perindopril may increase the hypotensive activities of Cryptenamine.
DB00796
Candesartan cilexetil may increase the hypotensive activities of Cryptenamine.
DB00800
Fenoldopam may increase the hypotensive activities of Cryptenamine.
DB00876
Eprosartan may increase the hypotensive activities of Cryptenamine.
DB00881
Quinapril may increase the hypotensive activities of Cryptenamine.
DB00960
Pindolol may increase the hypotensive activities of Cryptenamine.
DB00966
Telmisartan may increase the hypotensive activities of Cryptenamine.
DB00968
Methyldopa may increase the hypotensive activities of Cryptenamine.
DB01023
Felodipine may increase the hypotensive activities of Cryptenamine.
DB01029
Irbesartan may increase the hypotensive activities of Cryptenamine.
DB01054
Nitrendipine may increase the hypotensive activities of Cryptenamine.
DB01136
Carvedilol may increase the hypotensive activities of Cryptenamine.
DB01158
Bretylium may increase the hypotensive activities of Cryptenamine.
DB01162
Terazosin may increase the hypotensive activities of Cryptenamine.
DB01193
Acebutolol may increase the hypotensive activities of Cryptenamine.
DB01197
Captopril may increase the hypotensive activities of Cryptenamine.
DB01203
Nadolol may increase the hypotensive activities of Cryptenamine.
DB01244
Bepridil may increase the hypotensive activities of Cryptenamine.
DB01275
Hydralazine may increase the hypotensive activities of Cryptenamine.
DB01340
Cilazapril may increase the hypotensive activities of Cryptenamine.
DB01359
Penbutolol may increase the hypotensive activities of Cryptenamine.
DB01580
Oxprenolol may increase the hypotensive activities of Cryptenamine.
DB04861
Nebivolol may increase the hypotensive activities of Cryptenamine.
DB06712
Nilvadipine may increase the hypotensive activities of Cryptenamine.
DB08931
Riociguat may increase the hypotensive activities of Cryptenamine.
DB09026
Aliskiren may increase the hypotensive activities of Cryptenamine.
DB09235
Efonidipine may increase the hypotensive activities of Cryptenamine.
DB09236
Lacidipine may increase the hypotensive activities of Cryptenamine.
DB09477
Enalaprilat may increase the hypotensive activities of Cryptenamine.
DB11783
Imidapril may increase the hypotensive activities of Cryptenamine.
DB09237
Cryptenamine may increase the hypotensive activities of Levamlodipine.
DB00484
Brimonidine may increase the antihypertensive activities of Cryptenamine.
DB00203
Sildenafil may increase the antihypertensive activities of Cryptenamine.
DB00235
Milrinone may increase the antihypertensive activities of Cryptenamine.
DB00820
Tadalafil may increase the antihypertensive activities of Cryptenamine.
DB00862
Vardenafil may increase the antihypertensive activities of Cryptenamine.
DB00975
Dipyridamole may increase the antihypertensive activities of Cryptenamine.
DB05266
Ibudilast may increase the antihypertensive activities of Cryptenamine.
DB06237
Avanafil may increase the antihypertensive activities of Cryptenamine.
DB06267
Udenafil may increase the antihypertensive activities of Cryptenamine.
DB09273
Doxofylline may increase the antihypertensive activities of Cryptenamine.
DB11792
Mirodenafil may increase the antihypertensive activities of Cryptenamine.
DB12010
Fostamatinib may increase the antihypertensive activities of Cryptenamine.
DB00374
Treprostinil may increase the hypotensive activities of Cryptenamine.
DB01088
Iloprost may increase the hypotensive activities of Cryptenamine.
DB01240
Epoprostenol may increase the hypotensive activities of Cryptenamine.
DB00468
Quinine may increase the hypotensive activities of Cryptenamine.
DB14337
Salvia miltiorrhiza root may increase the hypotensive activities of Cryptenamine.
DB00182
Amphetamine may increase the hypotensive activities of Cryptenamine.
DB00601
Linezolid may increase the hypotensive activities of Cryptenamine.
DB00614
Furazolidone may increase the hypotensive activities of Cryptenamine.
DB00721
Procaine may increase the hypotensive activities of Cryptenamine.
DB00752
Tranylcypromine may increase the hypotensive activities of Cryptenamine.
DB00780
Phenelzine may increase the hypotensive activities of Cryptenamine.
DB00805
Minaprine may increase the hypotensive activities of Cryptenamine.
DB01037
Selegiline may increase the hypotensive activities of Cryptenamine.
DB01168
Procarbazine may increase the hypotensive activities of Cryptenamine.
DB01171
Moclobemide may increase the hypotensive activities of Cryptenamine.
DB01247
Isocarboxazid may increase the hypotensive activities of Cryptenamine.
DB01367
Rasagiline may increase the hypotensive activities of Cryptenamine.
DB01626
Pargyline may increase the hypotensive activities of Cryptenamine.
DB04017
Clorgiline may increase the hypotensive activities of Cryptenamine.
DB04818
Iproniazid may increase the hypotensive activities of Cryptenamine.
DB04820
Nialamide may increase the hypotensive activities of Cryptenamine.
DB06654
Safinamide may increase the hypotensive activities of Cryptenamine.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cryptenamine.
DB09241
Methylene blue may increase the hypotensive activities of Cryptenamine.
DB09243
Hydracarbazine may increase the hypotensive activities of Cryptenamine.
DB09244
Pirlindole may increase the hypotensive activities of Cryptenamine.
DB09245
Toloxatone may increase the hypotensive activities of Cryptenamine.
DB09246
Benmoxin may increase the hypotensive activities of Cryptenamine.
DB09248
Mebanazine may increase the hypotensive activities of Cryptenamine.
DB09249
Octamoxin may increase the hypotensive activities of Cryptenamine.
DB09250
Pheniprazine may increase the hypotensive activities of Cryptenamine.
DB09251
Phenoxypropazine may increase the hypotensive activities of Cryptenamine.
DB09252
Pivhydrazine may increase the hypotensive activities of Cryptenamine.
DB09253
Safrazine may increase the hypotensive activities of Cryptenamine.
DB09254
Caroxazone may increase the hypotensive activities of Cryptenamine.
DB13875
Harmaline may increase the hypotensive activities of Cryptenamine.
DB13876
Brofaromine may increase the hypotensive activities of Cryptenamine.
DB00159
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Icosapent.
DB00244
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Mesalazine.
DB00328
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Indomethacin.
DB00461
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Nabumetone.
DB00465
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ketorolac.
DB00469
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tenoxicam.
DB00482
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Celecoxib.
DB00500
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tolmetin.
DB00533
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Rofecoxib.
DB00554
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Fenoprofen.
DB00580
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Valdecoxib.
DB00586
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Diclofenac.
DB00605
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Sulindac.
DB00712
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Mefenamic acid.
DB00788
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Naproxen.
DB00795
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Sulfasalazine.
DB00812
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Phenylbutazone.
DB00814
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Meloxicam.
DB00821
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Carprofen.
DB00861
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Diflunisal.
DB00936
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Salicylic acid.
DB00939
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Meclofenamic acid.
DB00991
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Oxaprozin.
DB01009
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ketoprofen.
DB01014
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Balsalazide.
DB01050
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ibuprofen.
DB01250
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Olsalazine.
DB01283
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Lumiracoxib.
DB01397
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Antrafenine.
DB01424
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Aminophenazone.
DB01435
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tiaprofenic acid.
DB01628
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Etoricoxib.
DB02224
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Taxifolin.
DB03585
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Oxyphenbutazone.
DB04725
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Licofelone.
DB04743
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Nimesulide.
DB04812
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Benoxaprofen.
DB04817
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Metamizole.
DB04828
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Zomepirac.
DB05095
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Cimicoxib.
DB06725
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Aceclofenac.
DB06737
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Zaltoprofen.
DB07402
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Azapropazone.
DB08439
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Parecoxib.
DB08797
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Salicylamide.
DB08940
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Kebuzone.
DB08942
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Isoxicam.
DB08951
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Indoprofen.
DB08955
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ibuproxam.
DB08976
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Floctafenine.
DB08981
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Fenbufen.
DB08984
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Etofenamate.
DB08991
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Epirizole.
DB09084
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Benzydamine.
DB09213
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Dexibuprofen.
DB09214
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Dexketoprofen.
DB09215
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Droxicam.
DB09216
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tolfenamic acid.
DB09217
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Firocoxib.
DB09218
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Clonixin.
DB09285
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Morniflumate.
DB09288
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Propacetamol.
DB09295
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Talniflumate.
DB11455
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Robenacoxib.
DB11466
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tepoxalin.
DB11518
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Flunixin.
DB12399
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Polmacoxib.
DB12445
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Nitroaspirin.
DB12545
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Indobufen.
DB12610
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ebselen.
DB13001
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tinoridine.
DB13167
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Alclofenac.
DB13217
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Fentiazac.
DB13232
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Suxibuzone.
DB13286
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Bumadizone.
DB13314
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Alminoprofen.
DB13371
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Difenpiramide.
DB13407
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Nifenazone.
DB13432
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Lonazolac.
DB13481
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Tenidap.
DB13524
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Propyphenazone.
DB13527
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Proglumetacin.
DB13538
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Guacetisal.
DB13544
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ethenzamide.
DB13612
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Carbaspirin calcium.
DB13629
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Mofebutazone.
DB13649
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Proquazone.
DB13657
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Benorilate.
DB13722
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Pirprofen.
DB13783
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Acemetacin.
DB13860
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Imidazole salicylate.
DB14059
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with SC-236.
DB14060
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with NS-398.
DB14938
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Flurbiprofen axetil.
DB09212
The therapeutic efficacy of Cryptenamine can be decreased when used in combination with Loxoprofen.
DB09227
Cryptenamine may increase the antihypertensive activities of Barnidipine.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Cryptenamine.
DB00190
The risk or severity of hypotension can be increased when Carbidopa is combined with Cryptenamine.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Cryptenamine.
DB00041
Aldesleukin may increase the hypotensive activities of Cryptenamine.
DB00086
Streptokinase may increase the hypotensive activities of Cryptenamine.
DB00268
Ropinirole may increase the hypotensive activities of Cryptenamine.
DB00295
Morphine may increase the hypotensive activities of Cryptenamine.
DB00296
Ropivacaine may increase the hypotensive activities of Cryptenamine.
DB00297
Bupivacaine may increase the hypotensive activities of Cryptenamine.
DB00323
Tolcapone may increase the hypotensive activities of Cryptenamine.
DB00334
Olanzapine may increase the hypotensive activities of Cryptenamine.
DB00384
Triamterene may increase the hypotensive activities of Cryptenamine.
DB00413
Pramipexole may increase the hypotensive activities of Cryptenamine.
DB00421
Spironolactone may increase the hypotensive activities of Cryptenamine.
DB00435
Nitric Oxide may increase the hypotensive activities of Cryptenamine.
DB00486
Nabilone may increase the hypotensive activities of Cryptenamine.
DB00489
Sotalol may increase the hypotensive activities of Cryptenamine.
DB00594
Amiloride may increase the hypotensive activities of Cryptenamine.
DB00599
Thiopental may increase the hypotensive activities of Cryptenamine.
DB00631
Clofarabine may increase the hypotensive activities of Cryptenamine.
DB00661
Verapamil may increase the hypotensive activities of Cryptenamine.
DB00681
Amphotericin B may increase the hypotensive activities of Cryptenamine.
DB00697
Tizanidine may increase the hypotensive activities of Cryptenamine.
DB00703
Methazolamide may increase the hypotensive activities of Cryptenamine.
DB00706
Tamsulosin may increase the hypotensive activities of Cryptenamine.
DB00714
Apomorphine may increase the hypotensive activities of Cryptenamine.
DB00742
Mannitol may increase the hypotensive activities of Cryptenamine.
DB00755
Tretinoin may increase the hypotensive activities of Cryptenamine.
DB00872
Conivaptan may increase the hypotensive activities of Cryptenamine.
DB00883
Isosorbide dinitrate may increase the hypotensive activities of Cryptenamine.
DB00887
Bumetanide may increase the hypotensive activities of Cryptenamine.
DB00903
Etacrynic acid may increase the hypotensive activities of Cryptenamine.
DB00922
Levosimendan may increase the hypotensive activities of Cryptenamine.
DB01002
Levobupivacaine may increase the hypotensive activities of Cryptenamine.
DB01020
Isosorbide mononitrate may increase the hypotensive activities of Cryptenamine.
DB01041
Thalidomide may increase the hypotensive activities of Cryptenamine.
DB01113
Papaverine may increase the hypotensive activities of Cryptenamine.
DB01115
Nifedipine may increase the hypotensive activities of Cryptenamine.
DB01118
Amiodarone may increase the hypotensive activities of Cryptenamine.
DB01144
Diclofenamide may increase the hypotensive activities of Cryptenamine.
DB01169
Arsenic trioxide may increase the hypotensive activities of Cryptenamine.
DB01229
Paclitaxel may increase the hypotensive activities of Cryptenamine.
DB01235
Levodopa may increase the hypotensive activities of Cryptenamine.
DB01282
Carbetocin may increase the hypotensive activities of Cryptenamine.
DB01612
Amyl Nitrite may increase the hypotensive activities of Cryptenamine.
DB04899
Nesiritide may increase the hypotensive activities of Cryptenamine.
DB04920
Clevidipine may increase the hypotensive activities of Cryptenamine.
DB06292
Dapagliflozin may increase the hypotensive activities of Cryptenamine.
DB08822
Azilsartan medoxomil may increase the hypotensive activities of Cryptenamine.
DB08907
Canagliflozin may increase the hypotensive activities of Cryptenamine.
DB09038
Empagliflozin may increase the hypotensive activities of Cryptenamine.
DB09077
Dinutuximab may increase the hypotensive activities of Cryptenamine.
DB09112
Nitrous acid may increase the hypotensive activities of Cryptenamine.
DB09204
Arotinolol may increase the hypotensive activities of Cryptenamine.
DB09232
Cilnidipine may increase the hypotensive activities of Cryptenamine.
DB09279
Fimasartan may increase the hypotensive activities of Cryptenamine.
DB09286
Pipamperone may increase the hypotensive activities of Cryptenamine.
DB09292
Sacubitril may increase the hypotensive activities of Cryptenamine.
DB01238
The risk or severity of hypotension can be increased when Aripiprazole is combined with Cryptenamine.
DB14185
The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Cryptenamine.
DB00575
The risk or severity of hypotension can be increased when Clonidine is combined with Cryptenamine.
DB01224
Quetiapine may increase the hypotensive activities of Cryptenamine.
DB00246
Ziprasidone may increase the antihypertensive activities of Cryptenamine.
DB00606
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Cyclothiazide.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Cryptenamine.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Cryptenamine.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Cryptenamine.
DB00232
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Methyclothiazide.
DB00436
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Bendroflumethiazide.
DB00774
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Hydroflumethiazide.
DB00880
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Chlorothiazide.
DB00999
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Hydrochlorothiazide.
DB00562
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Benzthiazide.
DB13430
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Mebutizide.
DB00808
The therapeutic efficacy of Cryptenamine can be increased when used in combination with Indapamide.

序列

实验性质

外部标识符

resource：PubChem Substance
identifier：46507822
resource：PharmGKB
identifier：PA164749510
resource：Therapeutic Targets Database
identifier：DAP000479
resource：Wikipedia
identifier：Cryptenamine
resource：RxCUI
identifier：42618

外部链接

路径

目标

id:BE0000560
name:Muscarinic acetylcholine receptor M2
organism:Humans
action:antagonist
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
Jandhyala ML, Buckley JP: Mechanisms of action of cryptenamine. J Pharm Sci. 1968 Sep;57(9):1576-82.
Jandhyala BS, Buckley JP: Pharmacology and mechanism of action of cryptenamine. J Pharm Sci. 1966 Sep;55(9):888-93.
known-action:yes
name:Muscarinic acetylcholine receptor M2
general-function:G-protein coupled acetylcholine receptor activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.
gene-name:CHRM2
locus:7q31-q35
cellular-location:Cell membrane
transmembrane-regions:23-45 60-80 98-119 140-162 185-209 388-410 419-442
signal-regions:
theoretical-pi:9.08
molecular-weight:51714.605
chromosome-location:7
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1951GenAtlasCHRM2GenBank Gene DatabaseM16404GenBank Protein Database177990IUPHAR14Guide to Pharmacology14UniProtKBP08172UniProt AccessionACM2_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0016133|Muscarinic acetylcholine receptor M2 MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR
gene-sequence:>lcl|BSEQ0016134|Muscarinic acetylcholine receptor M2 (CHRM2) ATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA TTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG AACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC TTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC ACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA GCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC AGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA GGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC TTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT TTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC ATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC AAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA GTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC CAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG GAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA ATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT AAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT AATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT GTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC CGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG GCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT GTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT GCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG AACATAGGCGCTACAAGGTAA
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentneuronal cell bodycomponentplasma membranecomponentpostsynaptic membranecomponentsymmetric synapsecomponentsynapsefunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessnervous system developmentprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocessregulation of heart contractionprocessregulation of smooth muscle contractionprocessresponse to virusprocesssensory perception of chemical stimulusprocesssynaptic transmission, cholinergic
id:BE0004872
name:Beta adrenergic receptor
organism:Humans
action:inhibitor
action:potentiator
Jandhyala ML, Buckley JP: Mechanisms of action of cryptenamine. J Pharm Sci. 1968 Sep;57(9):1576-82.
known-action:unknown
name:Beta-1 adrenergic receptor
general-function:Receptor signaling protein activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
gene-name:ADRB1
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:56-84 94-120 133-154 173-196 223-248 320-349 355-377
signal-regions:
theoretical-pi:9.03
molecular-weight:51322.1
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:285GenAtlasADRB1GenBank Gene DatabaseJ03019GenBank Protein Database178200IUPHAR28Guide to Pharmacology28UniProtKBP08588UniProt AccessionADRB1_HUMAN
synonyms:ADRB1RB1ARBeta-1 adrenoceptorBeta-1 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010188|Beta-1 adrenergic receptor MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
gene-sequence:>lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1) ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG
pfams:PF000017tm_1
go-classifiers:componentearly endosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionbeta-adrenergic receptor activityfunctionbeta1-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionPDZ domain bindingfunctionprotein heterodimerization activityfunctionRas guanyl-nucleotide exchange factor activityfunctionreceptor signaling protein activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessbrown fat cell differentiationprocesscell-cell signalingprocessdiet induced thermogenesisprocessfear responseprocessheat generationprocessintracellular signal transductionprocessnegative regulation of multicellular organism growthprocesspositive regulation of cAMP biosynthetic processprocesspositive regulation of cAMP-mediated signalingprocesspositive regulation of GTPase activityprocesspositive regulation of heart rate by epinephrine-norepinephrineprocesspositive regulation of the force of heart contraction by epinephrine-norepinephrineprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure
name:Beta-2 adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
gene-name:ADRB2
locus:5q31-q32
cellular-location:Cell membrane
transmembrane-regions:35-58 72-95 107-129 151-174 197-220 275-298 306-329
signal-regions:
theoretical-pi:7.44
molecular-weight:46458.32
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:286GenAtlasADRB2GenBank Gene DatabaseY00106GenBank Protein Database29371IUPHAR29Guide to Pharmacology29UniProtKBP07550UniProt AccessionADRB2_HUMAN
synonyms:ADRB2RB2ARBeta-2 adrenoceptorBeta-2 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0037061|Beta-2 adrenergic receptor MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
gene-sequence:>lcl|BSEQ0020478|Beta-2 adrenergic receptor (ADRB2) ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA
pfams:PF000017tm_1
go-classifiers:componentapical plasma membranecomponentaxoncomponentdendritic spinecomponentearly endosomecomponentendosomecomponentintegral component of plasma membranecomponentlysosomecomponentneuronal cell body membranecomponentnucleuscomponentplasma membranecomponentreceptor complexcomponentsarcolemmafunctionbeta2-adrenergic receptor activityfunctiondopamine bindingfunctiondrug bindingfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionpotassium channel regulator activityfunctionprotein homodimerization activityprocessactivation of adenylate cyclase activityprocessactivation of transmembrane receptor protein tyrosine kinase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessagingprocessassociative learningprocessbone resorptionprocessbrown fat cell differentiationprocesscell surface receptor signaling pathwayprocesscell-cell signalingprocesscellular response to hypoxiaprocessdesensitization of G-protein coupled receptor protein signaling pathway by arrestinprocessdiaphragm contractionprocessdiet induced thermogenesisprocessendosome to lysosome transportprocessestrous cycleprocessexcitatory postsynaptic potentialprocessfemale pregnancyprocessheat generationprocessliver regenerationprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of angiogenesisprocessnegative regulation of inflammatory responseprocessnegative regulation of multicellular organism growthprocessnegative regulation of ossificationprocessnegative regulation of platelet aggregationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of urine volumeprocesspositive regulation of apoptotic processprocesspositive regulation of ATPase activityprocesspositive regulation of autophagosome maturationprocesspositive regulation of bone mineralizationprocesspositive regulation of cell proliferationprocesspositive regulation of lipophagyprocesspositive regulation of MAPK cascadeprocesspositive regulation of potassium ion transportprocesspositive regulation of protein ubiquitinationprocesspositive regulation of skeletal muscle tissue growthprocesspositive regulation of sodium ion transportprocesspositive regulation of the force of heart contraction by epinephrineprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of vasodilationprocessreceptor-mediated endocytosisprocessregulation of calcium ion transportprocessregulation of sensory perception of painprocessresponse to coldprocessresponse to dexamethasoneprocessresponse to estrogenprocessresponse to monoamineprocessresponse to progesteroneprocessresponse to testosteroneprocesssynaptic transmission, glutamatergicprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressureprocesswound healing
name:Beta-3 adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
gene-name:ADRB3
locus:8p12-p11.2
cellular-location:Cell membrane
transmembrane-regions:37-63 73-91 112-133 156-178 204-225 293-314 327-347
signal-regions:
theoretical-pi:9.07
molecular-weight:43518.615
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:288GenAtlasADRB3GenBank Gene DatabaseM29932GenBank Protein Database178896IUPHAR30Guide to Pharmacology30UniProtKBP13945UniProt AccessionADRB3_HUMAN
synonyms:ADRB3RB3ARBeta-3 adrenoceptorBeta-3 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010709|Beta-3 adrenergic receptor MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIV AIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLC VTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRV GADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRG ELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGT FTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLL CRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS
gene-sequence:>lcl|BSEQ0010710|Beta-3 adrenergic receptor (ADRB3) ATGGCTCCGTGGCCTCACGAGAACAGCTCTCTTGCCCCATGGCCGGACCTCCCCACCCTG GCGCCCAATACCGCCAACACCAGTGGGCTGCCAGGGGTTCCGTGGGAGGCGGCCCTAGCC GGGGCCCTGCTGGCGCTGGCGGTGCTGGCCACCGTGGGAGGCAACCTGCTGGTCATCGTG GCCATCGCCTGGACTCCGAGACTCCAGACCATGACCAACGTGTTCGTGACTTCGCTGGCC GCAGCCGACCTGGTGATGGGACTCCTGGTGGTGCCGCCGGCGGCCACCTTGGCGCTGACT GGCCACTGGCCGTTGGGCGCCACTGGCTGCGAGCTGTGGACCTCGGTGGACGTGCTGTGT GTGACCGCCAGCATCGAAACCCTGTGCGCCCTGGCCGTGGACCGCTACCTGGCTGTGACC AACCCGCTGCGTTACGGCGCACTGGTCACCAAGCGCTGCGCCCGGACAGCTGTGGTCCTG GTGTGGGTCGTGTCGGCCGCGGTGTCGTTTGCGCCCATCATGAGCCAGTGGTGGCGCGTA GGGGCCGACGCCGAGGCGCAGCGCTGCCACTCCAACCCGCGCTGCTGTGCCTTCGCCTCC AACATGCCCTACGTGCTGCTGTCCTCCTCCGTCTCCTTCTACCTTCCTCTTCTCGTGATG CTCTTCGTCTACGCGCGGGTTTTCGTGGTGGCTACGCGCCAGCTGCGCTTGCTGCGCGGG GAGCTGGGCCGCTTTCCGCCCGAGGAGTCTCCGCCGGCGCCGTCGCGCTCTCTGGCCCCG GCCCCGGTGGGGACGTGCGCTCCGCCCGAAGGGGTGCCCGCCTGCGGCCGGCGGCCCGCG CGCCTCCTGCCTCTCCGGGAACACCGGGCCCTGTGCACCTTGGGTCTCATCATGGGCACC TTCACTCTCTGCTGGTTGCCCTTCTTTCTGGCCAACGTGCTGCGCGCCCTGGGGGGCCCC TCTCTAGTCCCGGGCCCGGCTTTCCTTGCCCTGAACTGGCTAGGTTATGCCAATTCTGCC TTCAACCCGCTCATCTACTGCCGCAGCCCGGACTTTCGCAGCGCCTTCCGCCGTCTTCTG TGCCGCTGCGGCCGTCGCCTGCCTCCGGAGCCCTGCGCCGCCGCCCGCCCGGCCCTCTTC CCCTCGGGCGTTCCTGCGGCCCGGAGCAGCCCAGCGCAGCCCAGGCTTTGCCAACGGCTC GACGGGGCTTCTTGGGGAGTTTCTTAG
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentnucleuscomponentplasma membranecomponentreceptor complexfunctionbeta-adrenergic receptor activityfunctionbeta3-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionprotein homodimerization activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessagingprocessbrown fat cell differentiationprocesscarbohydrate metabolic processprocesscell-cell signalingprocessdiet induced thermogenesisprocesseating behaviorprocessenergy reserve metabolic processprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessgeneration of precursor metabolites and energyprocessheat generationprocessnegative regulation of multicellular organism growthprocesspositive regulation of MAPK cascadeprocessresponse to antibioticprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure

酶

载体

运输工具

药物反应

效应

不良反应